

Publications

Thura, M., Al-Aidaroos, A.Q., Gupta, A., Chee, C.E., Lee, S.C., Hui, K.M., Li, J., Yong, W.P., So, J., Chng, W.J., Ng, C.H., Zhou, J.B., Wong, L.Z., Yuen, S.P., Ho, S.S., Y., S.M., Chiong, E., Choo, S.P., Ngeow, J., Ng, C.H., Chua, C., Yeo, S.A., Tan, B.H., Sng, X.E., Tan, Y.Z., Zeng, Q, (2019) L3, -

PRL-3 induces EGFR activation and addiction in human cancer cells.

Journal of Clinical Investigation 123:3459-3471

Liu, H., Al-aidaroos, A.Q., Wang, H., Guo, K., Li, J., Zhang, H.F., and Zeng, Q. (2013)

PRL-3 suppresses c-

Tang, J.P.*, Tan, C.P.*, Li, J.*, Siddique, M.M., Guo, K., Chan, S.W., Park, J.E., Tay, W.N.,

Li, J., Guo, K., Koh, V.W.C., Tang, J.P., Gan, B.Q. Shi, H., Li, H.X. and Zeng, Q. (2005)
Generation of PRL-3 and PRL-1 specific monoclonal antibodies as potential diagnostic
markers for cancer metastases.

Clinical Cancer Research 11:2195-2204 (Cover).

Guo, K.*, Li, J.*, Tang, J.P.*, Koh, V., Gan, B.Q., and Zeng, Q. (2004)
Catalytic Domain of PRL-3 Plays an Essential Role in Tumor Metastasis; Formation of PRL-
3 tumors inside the blood vessels.

Cancer Biology & Therapy 3:945-951 (Cover with commentary).

* equal first authors

-

FEBS Lett, *Invited review*

Hong, C.W. and Zeng Q. (2012)

Awaiting a New Era of Cancer Immunotherapy.

Cancer Research 72: 3715-19.

Al-Aidaroos, A.Q., and Zeng, Q. (2010)

PRL-3 phosphatase and human cancers.

Journal of Cellular Biochemistry 111:1087-98 (Highlighted as Cover).

Zeng, Q., and Hong, W. (2008)

The emerging role of the Hippo pathway in cell contact inhibition, organ size control and cancer development in mammals (mini-review).

Cancer Cell 13:188-92.